Clinical Trial

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12-31 -> 2027-12-31 2026-08-04
minor Completion pushed: 2026-12-31 -> 2027-12-31 2026-08-04
Trial Details
NCT Number NCT06988319
Lead Sponsor Oregon Health and Science University
Collaborators: Portland Psychotherapy Clinic, Research, and Training Center
Conditions Chronic Pelvic Pain
Enrollment 15 participants
Start Date 2026-10-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-03